trial · primary record
HRS -4642 + SHR-1316+ Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection
Systemic Treatment-naïve Pancreatic Cancer
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 825 |
| Primary completion | 2030-12-30 |
| Primary endpoint | Event-Free Survival (EFS) based on Independent Review Committee according to RECIST v1.1 |
| Registry ID | NCT07900789 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:42:52.419Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07900789
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.